You are here: Industry Insights > Market News > Rare disease biotech Rallybio sets terms for $81 million IPO

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

3-Bromo-4-fluorobenzaldehyde

5-Methyl-1,3,4-oxadiazol2(3H)-one

4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride

4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine

3-Pyridinecarboxaldehyde

Ethyl 3 Fluorobenzoate

Rare disease biotech Rallybio sets terms for $81 million IPO

firstwordpharmaJuly 23, 2021

Tag: Rallybio , IPO , RLYB211

Favorites

Rallybio plans to raise $81 million in its initial public offering by offering 5.8 million shares at a price range of $13 to $15, as reported by NASDAQ.

The company is currently advancing its lead program, RLYB211, in a Phase I/II trial for the treatment of fetal and neonatal alloimmune thrombocytopenia (FNAIT).

RLYB211 is a polyclonal anti-HPA-1a antibody and is expected to report data from its Phase I/II trial this month.

The company also has four preclinical programs, one of which, RLBY212, is also being developed for the treatment of FNAIT, and two of which are being developed to treat complement dysregulation diseases.

Previous:TGA approves Pfizer COVID-19 vaccine for 12 to 15-year-olds

Next:Acticor Biotech Announces the Completion of Enrollment in its GARDEN Clinical Trial, a COVID-19-induced Acute Respiratory Distress Syndrome Efficacy Study

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Rare disease biotech Rallybio sets terms for $81 million IPO | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

Rare disease biotech Rallybio sets terms for $81 million IPO

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Rare disease biotech Rallybio sets terms for $81 million IPO

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may likeMore>>

You may like
More>>